Role of CX3CR1 Signaling in Malignant Transformation of Gliomas

Overview

Journal Neuro Oncol

Publisher Oxford University Press

Specialties Neurology
Oncology

Date 2020 Apr 3

PMID 32236410

Citations 26

Authors

Sungho Lee

Khatri Latha

Ganiraju Manyam

Yuhui Yang

Arvind Rao

Ganesh Rao

Affiliations

Soon will be listed here.

Abstract

Background: Chemokine signaling may contribute to progression of low-grade gliomas (LGGs) by altering tumor behavior or impacting the tumor microenvironment. In this study, we investigated the role of CX3C chemokine receptor 1 (CX3CR1) signaling in malignant transformation of LGGs.

Methods: Ninety patients with LGGs were genotyped for the presence of common CX3CR1 V249I polymorphism and examined for genotype-dependent alterations in survival, gene expression, and tumor microenvironment. A genetically engineered mouse model was leveraged to model endogenous intracranial gliomas with targeted expression of CX3C ligand 1 (CX3CL1) and CX3CR1, individually or in combination.

Results: LGG patients who were heterozygous (V/I; n = 43) or homozygous (I/I; n = 2) for the CX3CR1 V249I polymorphism had significantly improved median overall (14.8 vs 9.8 y, P < 0.05) and progression-free survival (8.6 vs 6.5 y, P < 0.05) compared with those with the wild type genotype (V/V; n = 45). Tumors from the V/I + I/I group exhibited significantly decreased levels of CCL2 and MMP9 transcripts, correlating with reduced intratumoral M2 macrophage infiltration and microvessel density. In an immunocompetent mouse model of LGGs, coexpression of CX3CL1 and CX3CR1 promoted a more malignant tumor phenotype characterized by increased microglia/macrophage infiltration and microvessel density, resulting in shorter survival.

Conclusions: CX3CR1 V249I polymorphism is associated with improved overall and progression-free survival in LGGs. CX3CR1 signaling enhances accumulation of tumor associated microglia/macrophages and angiogenesis during malignant transformation.

Citing Articles

Integrated electrophysiological and genomic profiles of single cells reveal spiking tumor cells in human glioma.

Curry R, Ma Q, McDonald M, Ko Y, Srivastava S, Chin P Cancer Cell. 2024; 42(10):1713-1728.e6.

PMID: 39241781 PMC: 11479845. DOI: 10.1016/j.ccell.2024.08.009.

Pediatric glioma immune profiling identifies TIM3 as a therapeutic target in BRAF fusion pilocytic astrocytoma.

Tripathi S, Najem H, Dussold C, Pacheco S, Du R, Sooreshjani M J Clin Invest. 2024; 134(19).

PMID: 39137048 PMC: 11444160. DOI: 10.1172/JCI177413.

"Find Me" and "Eat Me" signals: tools to drive phagocytic processes for modulating antitumor immunity.

Xiao L, Zhang L, Guo C, Xin Q, Gu X, Jiang C Cancer Commun (Lond). 2024; 44(7):791-832.

PMID: 38923737 PMC: 11260773. DOI: 10.1002/cac2.12579.

Microglia in Glioblastomas: Molecular Insight and Immunotherapeutic Potential.

Nusraty S, Boddeti U, Zaghloul K, Brown D Cancers (Basel). 2024; 16(11).

PMID: 38893093 PMC: 11171200. DOI: 10.3390/cancers16111972.

CX3CL1 (Fractalkine)-CX3CR1 Axis in Inflammation-Induced Angiogenesis and Tumorigenesis.

Szukiewicz D Int J Mol Sci. 2024; 25(9).

PMID: 38731899 PMC: 11083509. DOI: 10.3390/ijms25094679.

References

Doucette T, Kong L, Yang Y, Ferguson S, Yang J, Wei J . Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma. Neuro Oncol. 2012; 14(9):1136-45. PMC: 3424209. DOI: 10.1093/neuonc/nos139. View

Kim K, Vallon-Eberhard A, Zigmond E, Farache J, Shezen E, Shakhar G . In vivo structure/function and expression analysis of the CX3C chemokine fractalkine. Blood. 2011; 118(22):e156-67. PMC: 4507037. DOI: 10.1182/blood-2011-04-348946. View

Moatti D, Faure S, Fumeron F, Seknadji P, McDermott D, Debre P . Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood. 2001; 97(7):1925-8. DOI: 10.1182/blood.v97.7.1925. View

Stupp R, Hegi M, Mason W, van den Bent M, Taphoorn M, Janzer R . Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10(5):459-66. DOI: 10.1016/S1470-2045(09)70025-7. View

Platten M, Kretz A, Naumann U, Aulwurm S, Egashira K, Isenmann S . Monocyte chemoattractant protein-1 increases microglial infiltration and aggressiveness of gliomas. Ann Neurol. 2003; 54(3):388-92. DOI: 10.1002/ana.10679. View

Heimberger A, Abou-Ghazal M, Reina-Ortiz C, Yang D, Sun W, Qiao W . Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res. 2008; 14(16):5166-72. DOI: 10.1158/1078-0432.CCR-08-0320. View

Kong L, Wu A, Doucette T, Wei J, Priebe W, Fuller G . Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses. Clin Cancer Res. 2010; 16(23):5722-33. PMC: 2999668. DOI: 10.1158/1078-0432.CCR-10-1693. View

Dai C, Celestino J, Okada Y, Louis D, Fuller G, Holland E . PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev. 2001; 15(15):1913-25. PMC: 312748. DOI: 10.1101/gad.903001. View

Bhat K, Salazar K, Balasubramaniyan V, Wani K, Heathcock L, Hollingsworth F . The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev. 2011; 25(24):2594-609. PMC: 3248681. DOI: 10.1101/gad.176800.111. View

10.

Tom M, Park D, Yang K, Leyrer C, Wei W, Jia X . Malignant Transformation of Molecularly Classified Adult Low-Grade Glioma. Int J Radiat Oncol Biol Phys. 2019; 105(5):1106-1112. DOI: 10.1016/j.ijrobp.2019.08.025. View

11.

Egeblad M, Werb Z . New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002; 2(3):161-74. DOI: 10.1038/nrc745. View

12.

Ren F, Zhao Q, Huang L, Zheng Y, Li L, He Q . The R132H mutation in IDH1 promotes the recruitment of NK cells through CX3CL1/CX3CR1 chemotaxis and is correlated with a better prognosis in gliomas. Immunol Cell Biol. 2018; 97(5):457-469. DOI: 10.1111/imcb.12225. View

13.

Brat D, Verhaak R, Aldape K, Yung W, Salama S, Cooper L . Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med. 2015; 372(26):2481-98. PMC: 4530011. DOI: 10.1056/NEJMoa1402121. View

14.

Rodero M, Marie Y, Coudert M, Blondet E, Mokhtari K, Rousseau A . Polymorphism in the microglial cell-mobilizing CX3CR1 gene is associated with survival in patients with glioblastoma. J Clin Oncol. 2008; 26(36):5957-64. DOI: 10.1200/JCO.2008.17.2833. View

15.

Schaumberg D, Rose L, Deangelis M, Semba R, Hageman G, Chasman D . Prospective study of common variants in CX3CR1 and risk of macular degeneration: pooled analysis from 5 long-term studies. JAMA Ophthalmol. 2013; 132(1):84-95. PMC: 4170669. DOI: 10.1001/jamaophthalmol.2013.5506. View

16.

Xue Q, Cao L, Chen X, Zhao J, Gao L, Li S . High expression of MMP9 in glioma affects cell proliferation and is associated with patient survival rates. Oncol Lett. 2017; 13(3):1325-1330. PMC: 5403257. DOI: 10.3892/ol.2017.5567. View

17.

Buckner J, Shaw E, Pugh S, Chakravarti A, Gilbert M, Barger G . Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. N Engl J Med. 2016; 374(14):1344-55. PMC: 5170873. DOI: 10.1056/NEJMoa1500925. View

18.

Feng X, Szulzewsky F, Yerevanian A, Chen Z, Heinzmann D, Rasmussen R . Loss of CX3CR1 increases accumulation of inflammatory monocytes and promotes gliomagenesis. Oncotarget. 2015; 6(17):15077-94. PMC: 4558137. DOI: 10.18632/oncotarget.3730. View

19.

Wang M, Wang T, Liu S, Yoshida D, Teramoto A . The expression of matrix metalloproteinase-2 and -9 in human gliomas of different pathological grades. Brain Tumor Pathol. 2004; 20(2):65-72. DOI: 10.1007/BF02483449. View

20.

Ohgaki H, Kleihues P . The definition of primary and secondary glioblastoma. Clin Cancer Res. 2012; 19(4):764-72. DOI: 10.1158/1078-0432.CCR-12-3002. View